effect of duration and intermittency of rifampin on tuberculosis treatment outcomes a systematic review and meta-analysis效果持续时间和间歇性的利福平对肺结核治疗结果的系统回顾和荟萃分析.pdfVIP

Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis 1 1 1 1 2 1 Dick Menzies *, Andrea Benedetti , Anita Paydar , Ian Martin , Sarah Royce , Madhukar Pai , Andrew 3 4 5 Vernon , Christian Lienhardt , William Burman 1 Respiratory and Epidemiology Clinical Research Unit, Montreal Chest Institute Department of Epidemiology, Biostatistics Occupational Health, McGill University, Montreal, Canada, 2 University of California at San Francisco, San Francisco, California, United States of America, 3 Centers for Disease Control and Prevention, Atlanta, ´ Georgia, United States of America, 4 International Union against Tuberculosis and Lung Diseases, and Institut de Recherche pour le Developpement, Paris, France, 5 Denver Public Health, Denver, Colorado, United States of America Abstract Background: Treatment regimens for active tuberculosis (TB) that are intermittent, or use rifampin during only the initial phase, offer practical advantages, but their efficacy has been questioned. We conducted a systematic review of treatment regimens for active TB, to assess the effect of duration and intermittency of rifampin use on TB treatment outcomes. Methods and Findings: PubMed, Embase, and the Cochrane CENTRAL database for clinical trials were searched for randomized controlled trials, published in English, French, or Spanish, between 1965 and June 2008. Selected studies utilized standardized treatment with rifamp